Sanquin offers technologies for COVID-19 vaccines and immunotherapy

Sophisticated T cell technologies that help develop optimal SARS-CoV-2 vaccines or COVID-19 immune therapy are now on offer by Sanquin test service.

T cell involvement in the current corona virus outbreak appears to be very important. Sanquin’s one-off HLA peptide-binding- and HLA Tetramer Combinatorial Coding test service improves the selection of cytotoxic T cell epitopes significantly.

Peptide ranking based on in vitro HLA peptide-binding greatly optimizes the selection of candidate CD8+ T cell epitopes, showing the best correlation with immunogenicity.

Furthermore, HLA Tetramer Combinatorial Coding (HTCC) simultaneously analyses up to 41 different antigen-specific CD8+ T cell responses in a single patient sample and can be combined with extra- and intracellular flow cytometry. This contributes to in-depth characterization of antigen-specific T cell responses important for immunotherapeutic development and monitoring of immunotherapeutic interventions.

Visit our website for background information on these technologies or other cellular assays to aid your COVID related research. Or read the blog and view our poster about our latest results at Global-engage.com.

Feel free to send us an e-mail for more information!